Acumen Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Acumen Pharmaceuticals, Inc. (ABOS) had Deferred Tax Assets, Operating Loss Carryforwards of $50.39 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $50.39M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $20.91M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $16.55M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $13.13M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $50.39M 10-K · filed 2026-03-26 |
| 2024-12-31 | $20.91M 10-K · filed 2026-03-26 |
| 2023-12-31 | $16.55M 10-K · filed 2025-03-27 |
| 2022-12-31 | $13.13M 10-K · filed 2024-03-26 |
| 2021-12-31 | $10.82M 10-K · filed 2023-03-27 |
| 2020-12-31 | $6.35M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |